От открытия до дифференциации: почему подтипы лимфомы имеют значение



  1. Cowan DH. Vera Peters and the curability of Hodgkin disease. Curr Oncol. 2008; 15: 206-10.
  2. Hodgkin T. On Some Morbid Appearances of the absorbent glands and spleen. Med Chir Trans 1832; 17: 68-114.
  3. Lymphoma Research Foundation. About lymphoma. Available at: http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6299689. Last accessed September 2016.
  4. GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worldwide. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Last accessed September 2016.
  5. American Society of Hematology. Lymphoma. Available at: http://www.hematology.org/Patients/Cancers/Lymphoma.aspx Last accessed September 2016.
  6. Lyon, France: IARC Press. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. 2008.
  7. Shankland KR, et al. Non-Hodgkin lymphoma. Lancet. 2012; 380: 848-57.
  8. MedicineNet. Non-Hodgkin's Lymphoma: What are symptoms and signs of non-Hodgkin's lymphoma? Available at: http://www.medicinenet.com/non-hodgkins_lymphomas/page4.htm. Last accessed September 2016.
  9. National Institute for Health and Clinical Excellence. Review of TA 110: rituximab for the first-line treatment of stage III-IV follicular lymphoma. Available at: https://www.nice.org.uk/guidance/ta243/documents/follicular-lymphoma-rituximab-review-lymphoma-association2Last accessed September 2016.
  10. American Cancer Society. Types of non-Hodgkin lymphoma. Available at: http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodgkin-lymphomaLast accessed September 2016.
  11. Maurer, MJ et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014; 32: 1066-73.
  12. Liu Q, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006; 24: 1582-9.